FDA authorizes Byetta as adjunct therapy to insulin Lantus

10/19/2011 | Wall Street Journal, The

The FDA is allowing the use of Eli Lilly and Co. and Amylin Pharmaceuticals' type 2 diabetes medicine Byetta as an add-on to Sanofi's Lantus, or insulin glargine. Byetta can be taken with or without metformin and thiazolidinedione, and in addition to diet and exercise.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO